86 results on '"Kutomi G"'
Search Results
2. Abstract P5-11-03: Difference between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy for highly emetogenic chemotherapy in breast cancer patients – according to recent multi-institutional double-blind randomized clinical research on the AC regimen
- Author
-
Ogata, H, primary, Saito, M, additional, Tsuneizumi, M, additional, Kutomi, G, additional, Hosoya, K, additional, Kawai, Y, additional, Sugizaki, K, additional, Katsumata, N, additional, Senuma, K, additional, Kitabatake, T, additional, Suda, M, additional, Uomori, T, additional, Miura, K, additional, Kurata, M, additional, Nitta, Y, additional, Yonemoto, N, additional, and Matsuoka, J, additional
- Published
- 2017
- Full Text
- View/download PDF
3. P013 - Comparison between triplet antiemetic study (TTT) and doublet antiemetic study (PROTECT): insights into the mechanisms of serotonin and aprepitant actions in chemotherapy induced nausea and vomiting
- Author
-
Kutomi, G., Saito, M., Tsuneizumi, M., Ogata, H., Kawai, Y., Hosoya, K., Sugisaki, K., Katsumata, N., Nitta, Y., and Matsuoka, J.
- Published
- 2017
- Full Text
- View/download PDF
4. New Paradigm for Intrinsic Function of Heat Shock Proteins as Endogenous Ligands in Inflammation and Innate Immunity
- Author
-
Tamura, Y., primary, Torigoe, T., additional, Kutomi, G., additional, Hirata, K., additional, and Sato, N., additional
- Published
- 2012
- Full Text
- View/download PDF
5. 254 Oral Combination Chemotherapy with Capecitabine and Cyclophosphamide Showed Good Efficacy and Quality of Life for Metastatic Breast Cancer Patient
- Author
-
Kameshima, H., primary, Ohmura, T., additional, Kutomi, G., additional, Shima, H., additional, Takamaru, T., additional, Satomi, F., additional, Suzuki, Y., additional, Hirata, K., additional, and Otokozawa, S., additional
- Published
- 2012
- Full Text
- View/download PDF
6. Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells
- Author
-
Oura, J., primary, Tamura, Y., additional, Kamiguchi, K., additional, Kutomi, G., additional, Sahara, H., additional, Torigoe, T., additional, Himi, T., additional, and Sato, N., additional
- Published
- 2011
- Full Text
- View/download PDF
7. The potential for oral combination chemotherapy of 5′-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer
- Author
-
Yoshimoto, M, primary, Tada, K, additional, Tokudome, N, additional, Kutomi, G, additional, Tanabe, M, additional, Goto, T, additional, Nishimura, S, additional, Makita, M, additional, and Kasumi, F, additional
- Published
- 2003
- Full Text
- View/download PDF
8. A Case Report of Anorectal Malignant Melanoma with Superficial Pagetoid Spread
- Author
-
Hata, F., primary, Yasoshima, T., additional, Nishimori, H., additional, Ezoe, E., additional, Honma, T., additional, Nomura, H., additional, Furuhata, T., additional, Kimura, Y., additional, Kawasaki, H., additional, Yanai, Y., additional, Kutomi, G., additional, Ohno, K., additional, and Hirata, K., additional
- Published
- 2003
- Full Text
- View/download PDF
9. Prognostic Impact of Human Lymphocyte Antigen (HLA) Class I Expression in Patients With Breast Cancer.
- Author
-
Uchiyama M, Shima H, Kutomi G, Kyuno D, Wada A, Kuga Y, Tamura Y, Hirohashi Y, Torigoe T, and Takemasa I
- Subjects
- Humans, Female, Middle Aged, Prognosis, Aged, Adult, Biomarkers, Tumor metabolism, Disease-Free Survival, Kaplan-Meier Estimate, Aged, 80 and over, Lymphocytes, Tumor-Infiltrating immunology, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Immunohistochemistry, Breast Neoplasms immunology, Breast Neoplasms pathology, Breast Neoplasms mortality, Breast Neoplasms metabolism, Histocompatibility Antigens Class I metabolism
- Abstract
Background/aim: Various biomarkers are utilized in the field of breast cancer. Human lymphocyte antigen (HLA) class I molecules have a critical role in cancer immune surveillance. Therefore, this study aimed to assess the HLA class I expression and analyze the correlation with clinicopathologic factors in breast cancer., Patients and Methods: We investigated the clinical pathology archives of 150 consecutive patients with breast cancer who underwent a curative operation at the Sapporo Medical University, Japan, from January 2012 to December 2014. Immunohistochemical staining was used to evaluate HLA class I expression and CD8-positive T cell infiltration. The Pearson χ
2 test was used to assess HLA class I expression level and clinicopathological parameters. The Kaplan-Meier method was used to evaluate survival and the log-rank test to analyze the differences between survival curves., Results: Patients with dull/negative HLA class I had significantly poor disease-free survival (DFS) compared with those with positive HLA class I (p=0.0073). Univariate analyses revealed that pT, pN, positive lymphatic invasion, and dull/negative HLA class I were significantly associated with DFS. Multivariate analyses revealed dull/negative HLA class I as an independent poor prognostic factor (hazard ratio=2.75, 95% confidence interval=1.30-5.80, p=0.008)., Conclusion: HLA class I expression level may have a very sensitive prognostic effect on patients with breast cancer., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
10. Correction: The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
- Author
-
Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, and Saji S
- Published
- 2024
- Full Text
- View/download PDF
11. Multilayered proteomics reveals that JAM-A promotes breast cancer progression via regulation of amino acid transporter LAT1.
- Author
-
Magara K, Takasawa A, Takasawa K, Aoyama T, Ota M, Kyuno D, Ono Y, Murakami T, Yamamoto S, Nakamori Y, Nakahashi N, Kutomi G, Takemasa I, Hasegawa T, and Osanai M
- Abstract
Recent studies have shown that transmembrane-type tight junction proteins are upregulated in various cancers compared with their levels in normal tissues and are involved in cancer progression, suggesting that they are potential therapeutic targets. Here, we demonstrated the expression profile and a novel role of junctional adhesion molecule-A (JAM-A) in breast cancer. Immunohistochemistry of surgical specimens showed that JAM-A was highly expressed from carcinoma in situ lesions, as in other adenocarcinomas, with higher expression in invasive carcinomas. High expression of JAM-A contributed to malignant aspects such as lymph node metastasis and lymphatic involvement positivity. In breast cancer cells, JAM-A expression status affects malignant potentials including proliferation and migration. Multilayered proteomics revealed that JAM-A interacts with the amino acid transporter LAT1 in breast cancer cells. JAM-A regulates the expression of LAT1 and interacts with it on the whole cell membrane, leading to enhanced amino acid uptake to promote tumor growth. Double high expression of JAM-A and LAT1 predicts poor prognosis in patients with breast cancer. Of note, an antibody against an extracellular domain of JAM-A suppressed the proliferation of breast cancer cells. Our findings indicate the possibility of JAM-A-targeted therapy ideally combined with LAT1-targeted therapy as a new therapeutic strategy against breast cancer., (© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2024
- Full Text
- View/download PDF
12. Absolute lymphocyte count as a biomarker for best supportive care transition in metastatic breast cancer.
- Author
-
Horimoto Y, Jimbo H, Ishizuka Y, Nogami N, Kutomi G, and Watanabe J
- Abstract
Objectives: Time is crucial for patients with metastatic breast cancer (MBC), and clinicians are expected to determine the optimal timing for best supportive care (BSC) transition but no evident marker has been established. We recently revealed that absolute lymphocyte count (ALC) was a prognostic marker for patients with MBC. Thus, we investigated whether ALC could be an indicator of the best timing for the BSC transition., Methods: 101 patients with MBC were retrospectively investigated, and the relationship between clinicopathological factors, including ALC, and the duration of the last treatment was analysed., Results: Mean ALC significantly gradually decreased during the last three systemic treatments towards BSC transition. Patients of younger age, with special histology type, hormone receptor-positive tumours and low ALC at the start of the last treatment had significantly shorter time-to-treatment-termination (TTT) for the last treatment. When ALC was classified into low and high, the mean TTT of the last treatment in the ALC-low group was significantly shorter (16.4 weeks) compared with that in the ALC-high group (30.2 weeks; p=0.004)., Conclusions: Our data suggest that ALC values, which decrease as MBC progresses, could serve as a potential indicator for determining the optimal timing of BSC transition., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
13. The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
- Author
-
Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, and Saji S
- Subjects
- Humans, Female, Japan, Societies, Medical, Practice Guidelines as Topic, Medical Oncology standards, East Asian People, Breast Neoplasms therapy, Breast Neoplasms diagnosis, Breast Neoplasms pathology
- Abstract
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition was published in June 2022. The guidelines were prepared while conforming as much as possible to the "Minds Manual for Guideline Development 2020 ver. 3.0." edited by the Minds Manual Development Committee of the Japan Council for Quality Health Care in 2021. In addition, a survey of Japanese Breast Cancer Society members on the 2018 edition of the guidelines was conducted from February 19 to March 4, 2021. Based on the responses from over 600 members, original innovations were made to make the guidelines more user-friendly. The 2018 edition of the guidelines was developed to provide support tools for physicians and patients to utilize shared decision-making. The 2022 guidelines consist of two volumes: (1) an "Epidemiology and Diagnosis" section covering "Screening and Diagnosis", "Radiological diagnosis", and "Pathological diagnosis", and (2) a "Treatment" section covering "Surgical therapy", "Radiation therapy", and "Systemic therapy". We believe that this concise summary of the guidelines will be useful to physicians and researchers in Japan and overseas., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
14. The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.
- Author
-
Sakai T, Kutomi G, Shien T, Asaga S, Aruga T, Ishitobi M, Kuba S, Sawaki M, Terata K, Tomita K, Yamauchi C, Yamamoto Y, Iwata H, and Saji S
- Subjects
- Female, Humans, Decision Making, Japan, Breast Neoplasms pathology
- Abstract
The 2022 revision of the Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for surgical treatment of breast cancer was updated following a systematic review of the literature using the Medical Information Network Distribution Service (MINDS) procedure, which focuses on the balance of benefits and harms for various clinical questions (CQs). Experts in surgery designated by the JBCS addressed five areas: breast surgery, axillary surgery, breast reconstruction, surgical treatment for recurrent and metastatic breast cancer, and other related topics. The revision of the guidelines encompassed 4 CQs, 7 background questions (BQs), and 14 future research questions (FRQs). A significant revision in the 2022 edition pertained to axillary management after neoadjuvant chemotherapy in CQ2. The primary aim of the 2022 JBCS Clinical Practice Guidelines is to provide evidence-based recommendations to empower patients and healthcare professionals in making informed decisions regarding surgical treatment for breast cancer., (© 2023. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
15. Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain-containing 5.
- Author
-
Wada A, Hirohashi Y, Kutomi G, Murata K, Iwabuchi S, Mizue Y, Murai A, Kyuno D, Shima H, Minowa T, Sasaki K, Kubo T, Kanaseki T, Tsukahara T, Nakatsugawa M, Hashimoto S, Osanai M, Torigoe T, and Takemasa I
- Subjects
- Humans, Female, NLR Proteins, Caspase Activation and Recruitment Domain, Neoplasm Recurrence, Local, Receptors, Antigen, T-Cell metabolism, Antigens, Neoplasm, HLA Antigens, Intracellular Signaling Peptides and Proteins metabolism, Breast Neoplasms drug therapy, Breast Neoplasms genetics
- Abstract
Eribulin inhibits microtubule polymerization and improves the overall survival of patients with recurrent metastatic breast cancer. A subgroup analysis revealed a low neutrophil to lymphocyte ratio (NLR) (<3) to be a prognostic factor of eribulin treatment. We thus hypothesized that eribulin might be related to the immune response for breast cancer cells and we analyzed the effects of eribulin on the immune system. Immunohistochemical staining revealed that human leukocyte antigen (HLA) class I expression was increased in clinical samples after eribulin treatment. In vitro assays revealed that eribulin treatment increased HLA class I expression in breast cancer line cells. RNA-sequencing demonstrated that eribulin treatment increased the expression of the NOD-like family CARD domain-containing 5 (NLRC5), a master regulator of HLA class I expression. Eribulin treatment increased the NY-ESO-1-specific T-cell receptor (TCR) transduced T (TCR-T) cell response for New York oesophageal squamous cell carcinoma 1 (NY-ESO-1) overexpressed breast cancer cells. The eribulin and TCR-T combined therapy model revealed that eribulin and immunotherapy using TCR-T cells has a synergistic effect. In summary, eribulin increases the expression of HLA class 1 via HLA class 1 transactivatior NLRC5 and eribulin combination with immunotherapy can be effective for the treatment of breast cancer., (© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2023
- Full Text
- View/download PDF
16. Positional advantages of supine MRI for diagnosis prior to breast‑conserving surgery.
- Author
-
Kutomi G, Shima H, Kyuno D, Satomi F, Wada A, Kuga Y, Okazaki M, Okazaki A, Masuoka H, Mikami T, Yuyama Y, Matsuno T, Ohmura T, Kameshima H, Mizuguchi T, and Takemasa I
- Abstract
The present study aimed to evaluate the rate of positive surgical margins for magnetic resonance imaging (MRI) performed in the supine position prior to breast-conserving surgery (BCS). The rate of positive surgical margins and the clinicopathological factors were examined in consecutive patients with BCS who underwent preoperative MRI performed in the supine position at Sapporo Medical University Hospital (Sapporo, Japan) and related hospitals and clinics between January 2012 and December 2013. Of 1,175 eligible patients, 1,150 were included after excluding 25 patients with either bilateral breast cancer or stage IV disease. Positive margin was defined as no cancer seen on the resected margin. The primary endpoint was the rate of positive surgical margins when preoperative MRI was performed in the supine position and the secondary endpoint was identification of the factors that predict positive margins. Of the 1,150 female patients (median age, 55 years; range, 29-97 years) who underwent BCS for breast cancer following MRI performed in the supine position, 215 (18.8%) had positive margins, which is similar to the rate with MRI in the prone position, and 930 (81.2%) had negative margins. The rate of positive surgical margins in patients of the human epidermal growth factor receptor 2 (HER2) type was significantly higher than that in the non-HER2 type group (6.5 and 2.9%; χ
2 P=0.0103). There was no increase in the rate of positive margins in breast cancers with a diameter of >T2. The rate of positive surgical margins following MRI performed in the supine position was 18.8%. Supine MRI appears to be suitable for informing on the extent of resection of breast cancer., Competing Interests: The authors declare that they have no competing interests., (Copyright © 2020, Spandidos Publications.)- Published
- 2023
- Full Text
- View/download PDF
17. Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy.
- Author
-
Nakamura K, Ishitobi M, Oshiro C, Shima H, Takahashi E, Nakayama T, Shien T, Saito K, Iwatani T, Seto Y, Terata K, Kutomi G, Ogawa T, and Inaji H
- Subjects
- Humans, Animals, Female, Neoadjuvant Therapy, Prospective Studies, Breast, Breast Neoplasms drug therapy, Breast Neoplasms surgery, Mammary Neoplasms, Animal
- Abstract
Background/aim: Currently, several ongoing prospective studies are investigating the safety of breast surgery omission in patients with breast cancer who are exceptional responders to neoadjuvant chemotherapy. However, there is little information about the preferences of these patients regarding omission of breast surgery., Patients and Methods: We conducted a questionnaire survey to assess preferences regarding omission of breast surgery among patients with breast cancer who had human epidermal growth factor receptor 2-positive or estrogen receptor-negative tumors and good clinical response after neoadjuvant chemotherapy. Patients' estimation of the risk of ipsilateral breast tumor recurrence (IBTR) after definitive surgery or breast surgery omission was also assessed., Results: Of 93 patients, only 22 (23.7%) said they would omit breast surgery. Under the scenario of omitting breast surgery, the 5-year IBTR rate estimated by patients who said they would omit breast surgery was significantly lower (median, 10%) than the rate estimated by patients who preferred undergoing definitive surgery (median, 30%) (p=0.017)., Conclusion: The proportion of our surveyed patients who were willing to omit breast surgery was low. Patients who said they preferred to omit breast surgery overestimated the 5-year IBTR risk., (Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
18. Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy.
- Author
-
Shima H, Kutomi G, Kuga Y, Wada A, Satomi F, Sato K, Kyuno D, Nishikawa N, Uno S, Kameshima H, Ohmura T, Hasegawa T, and Takemasa I
- Abstract
The proper use of anthracycline-containing regimens in combination with anti-HER2-targeted therapy in a neoadjuvant setting for patients with HER2-positive breast cancer has not been resolved. Regimens preceded by anthracyclines have become the standard of care, and although the order has no significant impact on HER2-negative breast cancer, it is inconclusive as to whether a taxane-first sequence would have a similar effect on HER2-positive breast cancer. The present study aimed to investigate the benefit of a taxane-first sequence and of adriamycin and cyclophosphamide (AC) in patients with non-clinical complete response (non-cCR) to pertuzumab, trastuzumab and docetaxel (PTD). The present single-center prospective observational study was performed to investigate PTD followed by AC, and aimed to clarify the cCR rate after PTD alone and the pathological clinical response (pCR) rate after subsequent AC in patients without cCR after PTD alone. A total 24 patients were analyzed; of these, 14 achieved pCR (pCR rate, 58.3%). While four of 14 patients (28.6%) in the intention-to-treat population achieved pCR, nine of 14 patients (64.3%) achieved pCR with AC but not cCR after PTD. The median tumor reduction rate after four cycles of PTD was 58.9% (range, 20.8-100%) in all 24 patients, whereas the reduction rate after PTD-AC was 76.9% (range, 31.1-100%). Cardiac serious adverse events occurred in three patients (12.5%). In conclusion, a high pCR rate was observed for the taxane-first sequence. Patients were highly responsive to PTD, but some cases achieved additional antitumor effects after AC, which resulted in pCR without cCR after PTD alone. Since cardiotoxicity remains a significant problem, a higher risk-benefit treatment strategy is required to aim for AC omission. Trial registration number: UMIN000046338, name of registry: UMIN-CTR, date of registration: December 10, 2021., Competing Interests: The authors declare that they have no competing interests., (Copyright: © Shima et al.)
- Published
- 2022
- Full Text
- View/download PDF
19. YTHDC2 Promotes Malignant Phenotypes of Breast Cancer Cells.
- Author
-
Tanabe A, Nakayama T, Kashiyanagi J, Yamaga H, Hirohashi Y, Torigoe T, Satomi F, Shima H, Maeda H, Kutomi G, Takemasa I, and Sahara H
- Abstract
YTH domain-containing 2 (YTHDC2) is known to be an important regulator for RNA metabolism. Here, we show that YTHDC2 is essential for breast cancer tumorigenesis and metastasis. We examined YTHDC2 expression levels by immunohistochemistry in human breast tumor tissues from 99 patients and found a significantly positive correlation between the YTHDC2 expression level and the tumor stage. We established YTHDC2-knocked-down cell lines using four breast cancer cell lines with different subtypes. Knockdown of YTHDC2 attenuated the sphere-forming and the metastatic ability of breast cancer cells. Although stemness and EMT markers, such as SOX2, c-MYC, and NANOG, were downregulated in several YTHDC2-knocked-down breast cancer cells, a common target gene of YTHDC2 in breast cancer cells was not identified. These findings suggest that while YTHDC2 is involved in malignant progression of breast cancers, the mechanism by which YTHDC2 regulates those phenotypes is different between subtypes of breast cancers., Competing Interests: The authors declare no conflicts of interest for this article., (Copyright © 2022 Atsushi Tanabe et al.)
- Published
- 2022
- Full Text
- View/download PDF
20. Current standard values of health utility scores for evaluating cost-effectiveness in liver disease: A meta-analysis.
- Author
-
Ishinuki T, Ota S, Harada K, Kawamoto M, Meguro M, Kutomi G, Tatsumi H, Harada K, Miyanishi K, Kato T, Ohyanagi T, Hui TT, and Mizuguchi T
- Subjects
- Antiviral Agents, Cost-Benefit Analysis, Health Status, Humans, Quality of Life, Surveys and Questionnaires, Hepatitis C, Liver Diseases diagnosis, Liver Diseases therapy
- Abstract
Background: Health utility assessments have been developed for various conditions, including chronic liver disease. Health utility scores are required for socio-economic evaluations, which can aid the distribution of national budgets. However, the standard health utility assessment scores for specific health conditions are largely unknown., Aim: To summarize the health utility scores, including the EuroQOL 5-dimensions 5-levels (EQ-5D-5L), EuroQol-visual analogue scale, short from-36 (SF-36), RAND-36, and Health Utilities Index (HUI)-Mark2/Mark3 scores, for the normal population and chronic liver disease patients., Methods: A systematic literature search of PubMed and MEDLINE, including the Cochrane Library, was performed. Meta-analysis was performed using the RevMan software. Multiple means and standard deviations were combined using the StatsToDo online web program., Results: The EQ-5D-5L and SF-36 can be used for health utility evaluations during antiviral therapy for hepatitis C. HUI-Mark2/Mark3 indicated that the health utility scores of hepatitis B patients are roughly 30% better than those of hepatitis C patients., Conclusion: The EQ-5D-5L is the most popular questionnaire for health utility assessments. Health assessments that allow free registration would be useful for evaluating health utility in patients with liver disease., Competing Interests: Conflict-of-interest statement: All authors have nothing to disclose., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
21. An Optimal Timing for Removing a Drain After Breast Surgery: A Systematic Review and Meta-Analysis.
- Author
-
Shima H, Kutomi G, Sato K, Kuga Y, Wada A, Satomi F, Uno S, Nisikawa N, Kameshima H, Ohmura T, Mizuguchi T, and Takemasa I
- Subjects
- Female, Humans, Length of Stay, Mastectomy adverse effects, Seroma epidemiology, Seroma etiology, Seroma prevention & control, Surgical Wound Infection epidemiology, Surgical Wound Infection etiology, Surgical Wound Infection prevention & control, Breast Neoplasms surgery, Drainage adverse effects
- Abstract
Background: In clinical practice, drains had been routinely used for reducing seroma formation after breast surgery. However, an optimal timing to remove drains does not identify yet., Methods: This study aimed to compare the clinical outcome, such as seroma formation, surgical site infection (SSI), and a length of hospital stay between early removal and late removal. A systematic review was performed using PubMed, MEDLINE, and the Cochrane Library. Breast cancer patients who received surgery using drains were eligible. Those parameters were compared between early vs late removal., Results: Eleven studies included in this meta-analysis. Seroma formation in the early removal group was significantly higher than the one in the late removal group (RR = 1.58: 95%CI [1.25-2.01], P = 0.0001), meanwhile no significant difference was found among the groups for SSI (RR = 0.82: 95%CI [0.51-1.31], P= 0.40). A length of hospital stay in the early removal group was also significantly shorter than late removal (RR -3.31: 95%CI [-5.13-1.49], P = 0.0004)., Conclusions: Seroma formation was significantly higher in patients who had early drain removal. Conversely, SSI incidence was low, and early removal did not increase SSI incidence. In conclusion, early drain removal has no proved clinical benefit in these settings besides reduction of hospital stays., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
22. Correction to: The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.
- Author
-
Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, Hanamura N, Yano K, Wada N, Saji S, and Iwata H
- Published
- 2021
- Full Text
- View/download PDF
23. Comparing the extent of breast cancer tumors through contrast-enhanced ultrasound vs B-mode, opposed with pathology: evergreen study.
- Author
-
Shima H, Okuno T, Nakamura T, Noro A, Noma M, Sato M, Kaga T, Mituzuka Y, Kamei K, Imayoshi Y, Ito T, Kanazawa S, Kato K, Kutomi G, Sekiguchi R, Mori M, Tadashi H, Hirai T, and Takemasa I
- Subjects
- Aged, Breast Neoplasms epidemiology, Breast Neoplasms surgery, Female, Humans, Japan epidemiology, Mastectomy, Middle Aged, Retrospective Studies, Breast Neoplasms diagnostic imaging, Breast Neoplasms pathology, Contrast Media, Tumor Burden, Ultrasonography, Mammary methods
- Abstract
Background: To prove the efficacy of contrast-enhanced ultrasound (CEUS) in determining the extent of resection, more evidence about B-mode and CEUS as opposed to pathology is required. We compared maximum tumor width measured on B-mode/CEUS images with that determined pathologically., Methods: In this retrospective multicenter study, 152 operable breast cancer patients who had undergone both B-mode and CEUS were analyzed. Maximum tumor width on B-mode and CEUS, and on the postoperative pathological examination (P), was measured by the participating investigators. In addition, maximum width was assessed in B-mode and CEUS image sets by independent reviewers blinded to all patient information. We analyzed differences in maximum width between CEUS, B-mode and P., Results: The mean widths as measured by the participating investigators were 15 ± 7 mm (B-mode), 19 ± 8 mm (CEUS), and 17 ± 9 mm (P). The difference subtracted P from B-mode was - 3 ± 7 mm (p < 0.0001), and that from CEUS was 1 ± 6 mm (p = 0.0163). The mean widths as measured by the independent reviewers were 16 ± 7 mm (B-mode) and 18 ± 7 mm (CEUS). The difference subtracted P from B-mode was - 2 ± 8 mm (p = 0.0114), while that from CEUS was 1 ± 7 mm (p = 0.1921)., Conclusions: Maximum lesion width measurement showed a tendency to increase in the order of B-mode, to P and CEUS. The difference in measurement between P and B-mode was significant, but there was no significant between CEUS and P. These results provide additional information of tendency patterns in measuring the maximum lesion width through enhancement on CEUS.
- Published
- 2021
- Full Text
- View/download PDF
24. Erector spinae plane block versus retrolaminar block for postoperative analgesia after breast surgery: a randomized controlled trial.
- Author
-
Sotome S, Sawada A, Wada A, Shima H, Kutomi G, and Yamakage M
- Subjects
- Female, Humans, Pain, Postoperative drug therapy, Pain, Postoperative prevention & control, Paraspinal Muscles, Analgesia, Breast Neoplasms, Nerve Block
- Abstract
Purpose: The newly introduced erector spinae plane block (ESPB) has given anesthesiologists an alternative regional anesthetic technique for thoracic analgesia. Although ESPB and retrolaminar block (RLB) have similar puncture sites, no clinical study comparing ESPB and RLB has been reported. The aim of this study was to compare ESPB and RLB in terms of analgesic efficacy in the context of multimodal analgesia following breast surgery., Methods: Fifty female patients undergoing breast surgery under general anesthesia were randomly allocated to receive either ultrasound-guided ESPB or RLB with 20 mL of 0.375% levobupivacaine for postoperative analgesia. The primary outcome was analgesic efficacy in terms of time to first postoperative rescue analgesic after the block procedure. The secondary outcomes were consumption of remifentanil during anesthesia, pain intensity at rest for 24 h postoperatively, and occurrence of postoperative nausea and vomiting (PONV)., Results: After excluding five patients, 45 patients (22 and 23 patients in the ESPB and RLB group, respectively) were analyzed. Median time until the first postoperative rescue analgesic after the block procedure in the ESPB group was not significantly longer than that in the RLB group (8.6 [range 2.7-24] vs. 4.8 [3.0-24] h; P = 0.83). There was no significant difference in the consumption of remifentanil during anesthesia, pain intensity at rest for 24 h postoperatively, and occurrence of PONV between the two groups., Conclusion: ESPB is equivalent, and not superior, to RLB for postoperative analgesia after breast surgery when 20 mL of 0.375% levobupivacaine is injected at the fourth thoracic vertebra.
- Published
- 2021
- Full Text
- View/download PDF
25. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.
- Author
-
Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, Hanamura N, Yano K, Wada N, Saji S, and Iwata H
- Subjects
- Decision Support Techniques, Female, Humans, Japan, Medical Oncology organization & administration, Practice Guidelines as Topic, Breast Neoplasms surgery, Medical Oncology standards
- Abstract
We have prepared the Japanese Breast Cancer Society clinical practice guidelines (CPGs) for surgical treatment of breast cancer, 2018 update after a systematic review (SR) of the literature based upon the Medical Information Network Distribution Service (Minds) procedure. The CPG committee for surgical treatment of breast cancer, composed of breast surgeons and plastic surgeons treating breast cancer, has developed the CPGs. Eight clinical questions (CQs) were selected and divided roughly into the following five categories: (1) breast surgery in initial therapy (CQs 1-3); (2) axillary surgery in initial therapy (CQs 4-5); (3) breast reconstruction in initial therapy (CQ 6); (4) surgical treatment for recurrent and metastatic breast cancer (CQs 7-8); and (5) others. Recommendations for these CQs were decided by the GRADE grid method. In addition, 4 outlines, 14 background questions (BQs), and 12 future research questions (FQs) were also selected. Statements for these BQs and FQs are provided. We developed the updated CPGs for surgical treatment of breast cancer, 2018, which include 8 CQs and recommendations. As a decision-making tool for the understanding and treatment of breast cancer, these guidelines will help surgical oncologists dealing with breast cancer, medical staff, and patients, along with their family members.
- Published
- 2020
- Full Text
- View/download PDF
26. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
- Author
-
Shima H, Tsurita G, Wada S, Hirohashi Y, Yasui H, Hayashi H, Miyakoshi T, Watanabe K, Murai A, Asanuma H, Tokita S, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nakae Y, Sugita O, Ito YM, Ota Y, Kimura Y, Kutomi G, Hirata K, Mizuguchi T, Imai K, Takemasa I, Sato N, and Torigoe T
- Subjects
- Adult, Aged, Aged, 80 and over, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Double-Blind Method, Female, Humans, Male, Middle Aged, Prognosis, Progression-Free Survival, Vaccination methods, Vaccines, Subunit therapeutic use, Gemcitabine, Pancreatic Neoplasms, Adenocarcinoma drug therapy, Cancer Vaccines therapeutic use, Interferon-beta therapeutic use, Pancreatic Neoplasms drug therapy, Peptides therapeutic use, Survivin therapeutic use
- Abstract
The prognosis of advanced pancreatic adenocarcinoma is still extremely poor. This study sought to determine the efficacy of, and immunological response to, peptide vaccination therapy in patients with this disease. In this multicenter randomized phase II study, patients with advanced pancreatic adenocarcinoma after gemcitabine and/or tegafur/gimeracil/oteracil were randomly assigned to 3 groups that each received a 2-step treatment course. In Step 1, the groups received treatments of: (i) survivin 2B peptide (SVN-2B) plus interferon-β (IFNβ); (ii) SVN-2B only; or (iii) placebo until the patients show progression. In Step 2, all patients who consented to participate received 4 treatments with SVN-2B plus IFNβ. The primary endpoint was progression-free survival (PFS) after initiation of Step 1 treatment. Secondary endpoints included immunological effects assessed by analysis of PBMCs after Step 1. Eighty-three patients were randomly assigned to receive SVN-2B plus IFNβ (n = 30), SVN-2B (n = 34), or placebo (n = 19). No significant improvement in PFS was observed. Survivin 2B-specific CTLs were found to be increased in the SVN-2B plus IFNβ group by tetramer assay. Among patients who participated in Step 2, those who had received SVN-2B plus IFNβ in Step 1 showed better overall survival compared with those who had received placebo in Step 1. Patients vaccinated with SVN-2B plus IFNβ did not have improved PFS, but showed significant immunological reaction after vaccination. Subgroup analysis suggested that a longer SVN-2B plus IFNβ vaccination protocol might confer survival benefit. (Clinical trial registration number: UMIN 000012146)., (© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2019
- Full Text
- View/download PDF
27. Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy.
- Author
-
Kitagawa M, Someya M, Hasegawa T, Mikami T, Asaishi K, Hasegawa T, Matsumoto Y, Kutomi G, Takemasa I, and Sakata KI
- Subjects
- Adult, Aged, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma, Ductal mortality, Carcinoma, Ductal pathology, Carcinoma, Lobular mortality, Carcinoma, Lobular pathology, Cohort Studies, Female, Humans, Middle Aged, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Neoplasms, Second Primary genetics, Neoplasms, Second Primary mortality, Neoplasms, Second Primary pathology, Prognosis, Propensity Score, Survival Rate, Breast Neoplasms genetics, Breast Neoplasms surgery, Carcinoma, Ductal genetics, Carcinoma, Lobular genetics, DNA-Binding Proteins genetics, Mastectomy, Segmental, Neoplasm Recurrence, Local genetics
- Abstract
Background: We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was a difference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a new primary tumor (NP)., Patients and Methods: The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40 patients with IBTR. Propensity score matching was employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens., Results: The 40 patients with IBTR included 22 patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP., Conclusion: IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.
- Published
- 2019
- Full Text
- View/download PDF
28. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine.
- Author
-
Shima H, Kutomi G, Satomi F, Imamura M, Kimura Y, Mizuguchi T, Watanabe K, Takahashi A, Murai A, Tsukahara T, Kanaseki T, Hirohashi Y, Iwayama Y, Tsuruma T, Kameshima H, Sato N, Torigoe T, and Takemasa I
- Subjects
- Cancer Vaccines immunology, Female, Humans, Immunization, Middle Aged, Pancreatic Neoplasms immunology, Pancreatic Neoplasms therapy, Prognosis, Survivin, Vaccines, Subunit immunology, Vaccines, Subunit therapeutic use, Cancer Vaccines therapeutic use, Inhibitor of Apoptosis Proteins immunology, Pancreatic Neoplasms mortality, T-Lymphocytes, Cytotoxic immunology
- Abstract
A 62-year-old woman who underwent surgery to treat pancreatic cancer provided written, informed consent to undergo adjuvant therapy with gemcitabine, tegafur, and uracil. However, this was stopped after only 14 days due to Grade 4 neutropenia. She was then started on vaccine therapy with Survivin 2B peptide (SVN-2B) including IFA and INF-α. Although metastatic lung tumors were identified and resected at 82 months after surgery, the patient has remained free of new or relapsed disease for 12 years thereafter. Tetramer and ELISPOT assays revealed the continuous circulation of SVN-2B-restricted cytotoxic T-lymphocytes (CTLs) in her peripheral blood, and CTL clones had specific activity for SVN-2B at 12 years after surgery. The adverse effects of the peptide vaccination were tolerable and comprised low-grade headache, nausea, and fatigue. A prognosis beyond 10 years in the face of pancreatic cancer with distant metastasis is extremely rare. This experience might indicate the value of cancer vaccination therapy.
- Published
- 2018
- Full Text
- View/download PDF
29. A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study.
- Author
-
Onishi H, Udagawa C, Kubo M, Nakamura S, Akashi-Tanaka S, Kuwayama T, Watanabe C, Takamaru T, Takei H, Ishikawa T, Miyahara K, Matsumoto H, Hasegawa Y, Momozawa Y, Low SK, Kutomi G, Shima H, Satomi F, Okazaki M, Zaha H, Onomura M, Matsukata A, Sagara Y, Baba S, Yamada A, Shimada K, Shimizu D, Tsugawa K, Shimo A, Hartman M, Chan CW, Lee SC, Endo I, and Zembutsu H
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms surgery, Chromosomes, Human genetics, Female, Humans, Ki-67 Antigen metabolism, Middle Aged, Preoperative Care, Prospective Studies, Receptor, ErbB-2 metabolism, Sequence Analysis, DNA, Tamoxifen pharmacology, Treatment Outcome, Breast Neoplasms drug therapy, Genetic Markers drug effects, Genome-Wide Association Study methods, Polymorphism, Single Nucleotide, Tamoxifen therapeutic use
- Abstract
Purpose: Although association studies of genetic variations with the clinical outcomes of breast cancer patients treated with tamoxifen have been reported, genetic factors which could determine individual response to tamoxifen are not fully clarified. We performed a genome-wide association study (GWAS) to identify novel genetic markers for response to tamoxifen., Experimental Design: We prospectively collected 347 blood samples from patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative, invasive breast cancer receiving preoperative tamoxifen monotherapy for 14 to 28 days. We used Ki-67 response in breast cancer tissues after preoperative short-term tamoxifen therapy as a surrogate marker for response to tamoxifen. We performed GWAS and genotype imputation using 275 patients, and an independent set of 72 patients was used for replication study., Results: The combined result of GWAS and the replication study, and subsequent imputation analysis indicated possible association of three loci with Ki-67 response after tamoxifen therapy (rs17198973 on chromosome 4q34.3, rs4577773 on 6q12, and rs7087428 on 10p13, Pcombined = 5.69 x 10-6, 1.64 x 10-5, and 9.77 x 10-6, respectively). When patients were classified into three groups by the scoring system based on the genotypes of the three SNPs, patients with higher scores showed significantly higher after/before ratio of Ki-67 compared to those with lower scores (P = 1.8 x 10-12), suggesting the cumulative effect of the three SNPs., Conclusion: We identified three novel loci, which could be associated with clinical response to tamoxifen. These findings provide new insights into personalized hormonal therapy for the patients with breast cancer., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
30. Comparison of surgical outcomes and complications between the Harmonic FOCUS and conventional surgery for open thyroidectomy.
- Author
-
Maeda H, Kutomi G, Satomi F, Shima H, Mori M, and Takemasa I
- Abstract
The aim of the present study was to evaluate the potential advantages of the ultrasonic scalpel compared with the conventional technique in thyroid surgery. Patients with resectable thyroid cancer and Basedow's disease were assigned to ultrasonic scalpel or conventional technique (knot-tying and electrocoagulation). The present study used the Harmonic FOCUS
® (HF) as an ultrasonic scalpel. Between February 2013 and May 2016, 45 patients were enrolled into the study. Duration of the surgery was significantly decreased in the HF group compared with the conventional surgery (CS) group (median 142 vs. 151 min; P=0.0406). Intraoperative blood loss and total volume of drainage fluid were significantly decreased in the HF group compared with the CS group (median 40 vs. 125 ml; P=0.0054, and median 120 vs. 175.5 ml; P=0.0490). Duration of drain placement and length of hospitalization stay were similar in the two groups. Furthermore, the overall incidence of postoperative complications did not differ between the two groups. Overall, the present study suggests that open thyroidectomy using the HF is safe and effective and not associated with any increase in complications.- Published
- 2018
- Full Text
- View/download PDF
31. ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway.
- Author
-
Ogawa T, Hirohashi Y, Murai A, Nishidate T, Okita K, Wang L, Ikehara Y, Satoyoshi T, Usui A, Kubo T, Nakastugawa M, Kanaseki T, Tsukahara T, Kutomi G, Furuhata T, Hirata K, Sato N, Mizuguchi T, Takemasa I, and Torigoe T
- Abstract
Colorectal cancer (CRC) is a mortal disease due to treatment resistance, recurrence and distant metastasis. Emerging evidence has revealed that a small sub-population of cancer cells termed cancer stem cells (CSCs)/ cancer-initiating cells (CICs) is endowed with high levels of tumor-initiating ability, self-renewal ability and differentiation ability and is responsible for treatment resistance, recurrence and distant metastasis. Eradication of CSCs/CICs is essential to improve current treatments. However, the molecular mechanisms by which CSCs/CICs are maintained are still elusive. In this study, we aimed to determine the molecular mechanisms by which colorectal (CR)-CSCs/CICs in are maintained human primary CRC cells. CR-CSCs/CICs were isolated by sphere-culture and the ALDEFLUOR assay, and transcriptome analysis revealed that the gene ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 1 (ST6GALNAC1) was expressed at high levels in CR-CSCs/CICs. Overexpression of ST6GALNAC1 enhanced the expression of sialyl-Tn (STn) antigen, which is carried by the CSC marker CD44, and increased the sphere-forming ability and resistance to a chemotherapeutic reagent. The opposite phenomena were observed by gene knockdown using siRNA. Furthermore, the Akt pathway was activated in ST6GANAC1-overexpressed cells, and activation of the pathway was cancelled by gene knockdown of galectin-3. The results indicate that ST6GALNAC1 has a role in the maintenance of CR-CSCs/CICs by activating the Akt pathway in cooperation with galectin-3 and that ST6GalNAC1 (or STn antigen) might be a reasonable molecule for CSC/CIC-targeting therapy., Competing Interests: CONFLICTS OF INTEREST The authors have no conflicts of interest.
- Published
- 2017
- Full Text
- View/download PDF
32. LY6/PLAUR domain containing 3 has a role in the maintenance of colorectal cancer stem-like cells.
- Author
-
Wang L, Hirohashi Y, Ogawa T, Shen M, Takeda R, Murai A, Yamamoto E, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nishidate T, Okita K, Kutomi G, Sato N, Takemasa I, and Torigoe T
- Subjects
- Aldehyde Dehydrogenase genetics, Aldehyde Dehydrogenase metabolism, Aldehyde Dehydrogenase 1 Family, Cell Adhesion Molecules antagonists & inhibitors, Cell Adhesion Molecules metabolism, Cell Line, Tumor, Cell Proliferation, GPI-Linked Proteins antagonists & inhibitors, GPI-Linked Proteins genetics, GPI-Linked Proteins metabolism, HCT116 Cells, HT29 Cells, Humans, Nanog Homeobox Protein genetics, Nanog Homeobox Protein metabolism, Neoplastic Stem Cells pathology, Octamer Transcription Factor-3 genetics, Octamer Transcription Factor-3 metabolism, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Retinal Dehydrogenase, SOXB1 Transcription Factors genetics, SOXB1 Transcription Factors metabolism, Signal Transduction, Spheroids, Cellular pathology, Cell Adhesion Molecules genetics, Gene Expression Regulation, Neoplastic, Neoplastic Stem Cells metabolism, Spheroids, Cellular metabolism
- Abstract
Colorectal carcinoma (CRC) is one of the most frequently diagnosed cancers and the leading cause of cancer-related death for both men and women. Recent studies have revealed that a small sub-population of cancer cells, termed cancer stem-like cells (CSCs)/cancer-initiating cells (CICs), are endowed with tumor-initiating ability, self-renewal ability and differentiation ability. CSCs/CICs are resistant to current therapies including chemotherapy and radiotherapy. Thus, CSCs/CICs are responsible for recurrence and metastasis, and eradication of CSCs/CICs is essential to cure cancer. In this study, we isolated CR-CSCs/CICs as sphere-cultured cells and found that a product derived from LY6/PLAUR domain containing 3 (LYPD3) is preferentially expressed in CSCs/CICs. Gene overexpression and gene knockdown experiments revealed that LYPD3 has a role in the maintenance of CR-CSCs/CICs. The findings provide a novel molecular insight into CR-CSCs/CICs., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
33. Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.
- Author
-
Zembutsu H, Nakamura S, Akashi-Tanaka S, Kuwayama T, Watanabe C, Takamaru T, Takei H, Ishikawa T, Miyahara K, Matsumoto H, Hasegawa Y, Kutomi G, Shima H, Satomi F, Okazaki M, Zaha H, Onomura M, Matsukata A, Sagara Y, Baba S, Yamada A, Shimada K, Shimizu D, Tsugawa K, Shimo A, Tan EY, Hartman M, Chan CW, Lee SC, and Nakamura Y
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Genotype, Humans, Ki-67 Antigen analysis, Middle Aged, Polymorphism, Single Nucleotide, Prospective Studies, Treatment Outcome, Antineoplastic Agents, Hormonal therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Cytochrome P-450 CYP2D6 genetics, Tamoxifen therapeutic use
- Abstract
Purpose: CYP2D6 is the key enzyme responsible for the generation of the potent active metabolite of tamoxifen, "endoxifen." There are still controversial reports questioning the association between CYP2D6 genotype and tamoxifen efficacy. Hence, we performed a prospective multicenter study to evaluate the clinical effect of CYP2D6 genotype on tamoxifen therapy. Experimental Design: We enrolled 279 patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative, invasive breast cancer receiving preoperative tamoxifen monotherapy for 14 to 28 days. Ki-67 response in breast cancer tissues after tamoxifen therapy was used as a surrogate marker for response to tamoxifen. We prospectively investigated the effects of allelic variants of CYP2D6 on Ki-67 response, pathological response, and hot flushes. Results: Ki-67 labeling index in breast cancer tissues significantly decreased after preoperative tamoxifen monotherapy ( P = 0.0000000000000013). Moreover, proportion and Allred scores of estrogen receptor-positive cells in breast cancer tissues were significantly associated with Ki-67 response ( P = 0.0076 and 0.0023, respectively). Although CYP2D6 variants were not associated with pathologic response nor hot flushes, they showed significant association with Ki-67 response after preoperative tamoxifen therapy ( P = 0.018; between two groups, one with at least one wild-type allele and the other without a wild-type allele). Conclusions: This is the first prospective study evaluating the relationship between CYP2D6 variants and Ki-67 response after tamoxifen therapy. Our results suggest that genetic variation in CYP2D6 is a key predictor for the response to tamoxifen in patients with breast cancer. Clin Cancer Res; 23(8); 2019-26. ©2016 AACR ., (©2016 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
34. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer.
- Author
-
Tanaka T, Kutomi G, Kajiwara T, Kukita K, Kochin V, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Okamoto Y, Hirata K, Sato N, and Tamura Y
- Subjects
- Apoptosis immunology, B7-H1 Antigen biosynthesis, Breast Neoplasms pathology, Cell Line, Tumor, Female, Humans, Interferon-gamma pharmacology, Jurkat Cells, Leukemia, T-Cell enzymology, Membrane Glycoproteins antagonists & inhibitors, Membrane Glycoproteins biosynthesis, Oxidoreductases antagonists & inhibitors, Oxidoreductases biosynthesis, Protein Folding, Transfection, Triple Negative Breast Neoplasms enzymology, Triple Negative Breast Neoplasms immunology, Tumor Escape, Up-Regulation drug effects, Up-Regulation immunology, B7-H1 Antigen immunology, Breast Neoplasms immunology, Leukemia, T-Cell immunology, Membrane Glycoproteins immunology, Oxidoreductases immunology
- Abstract
Many human cancers have been reported to have enhanced expression of the immune checkpoint molecule programmed death-ligand 1 (PD-L1), which binds to programmed cell death-1 (PD-1) expressed on immune cells. PD-L1/PD-1 plays a role in inhibition of antitumor immunity by inducing T cell apoptosis and tolerance. Thus, it is crucial to elucidate mechanisms of PD-L1 expression on cancer cells. ERO1-α is an oxidase located in the endoplasmic reticulum. It is overexpressed in a variety of tumor types and it plays a role in disulfide bond formation in collaboration with PDI. Here, we investigated the influence of ERO1-α on expression of PD-L1 and immune escape. We demonstrated that ERO1-α augmented the expression of PD-L1 via facilitation of oxidative protein folding within PD-L1. In addition, we showed that overexpression of ERO1-α increased HIF-1α protein expression, resulting in an increase of PD-L1 mRNA as well as protein. In clinical cases, we observed that the expression of ERO1-α in triple negative breast cancer was related to the expression of PD-L1. Moreover, apoptosis of Jurkat leukemia T cells, which express PD-1, induced by tumor PD-L1 was inhibited when ERO1-α was depleted. The results suggest that targeting ERO1-α in tumor cells can be a novel approach for cancer immunotherapy. Therefore, the role of ERO1-α in tumor-mediated immunosuppression should be further explored.
- Published
- 2017
- Full Text
- View/download PDF
35. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
- Author
-
Takeda R, Hirohashi Y, Shen M, Wang L, Ogawa T, Murai A, Yamamoto E, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Nishidate T, Okita K, Kutomi G, Sato N, Takemasa I, and Torigoe T
- Subjects
- Cell Line, Tumor, Cell Proliferation genetics, Cell Survival genetics, Colorectal Neoplasms pathology, Female, HCT116 Cells, HT29 Cells, Humans, Male, Neoplastic Stem Cells pathology, Protein Isoforms genetics, RNA Interference, RNA Splicing, Reverse Transcriptase Polymerase Chain Reaction, Spheroids, Cellular metabolism, Testis metabolism, Colorectal Neoplasms genetics, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Neoplasm Proteins genetics, Neoplastic Stem Cells metabolism
- Abstract
Colorectal cancer (CRC) is one of the most common malignancy, and the prognosis is not still satisfactory due to treatment resistance, recurrence and distant metastasis. Cancer stem cells (CSCs)/cancer-initiating cells (CICs) is endowed with higher tumor-initiating ability, self-renewal ability and differentiation ability, and CSCs/CICs are resistant to treatments. Thus, CSCs/CICs are thought to be responsible for recurrence and distant metastasis, and eradication of CSCs/CICs is essential to cure CRCs. However, the molecular mechanisms of CSCs/CICs are remain unknown, and we aimed to elucidate molecular aspects of CR-CSCs/CICs in this study. We screened the transcriptome data of primary human CR-CSCs/CICs that we previously established, and found that LEM domain containing 1 (LEMD1) is preferentially expressed in CR-CSCs/CICs. LEMD1 belongs to cancer-testis (CT) antigen, and has five transcript variants (variant 1 [V1] - variant 5 [V5]). We found that LEMD1 V1, V2 and V3 is expressed in testis and CR-CSCs/CICs, whereas LEMD1 V4 and V5 is ubiquitously expressed. LEMD1 gene knockdown experiments using siRNAs and gene overexpression experiments revealed that LEMD1 has a role in the maintenance of CR-CSCs/CICs. These observations indicate that CR-CSC/CIC-specific LEMD1 variants are reasonable target of CR-CSC/CIC-targeted therapy., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
36. Current status of the prognostic molecular biomarkers in breast cancer: A systematic review.
- Author
-
Kutomi G, Mizuguchi T, Satomi F, Maeda H, Shima H, Kimura Y, and Hirata K
- Abstract
Biomarkers that facilitate the prediction of breast cancer prognosis can improve the quality of life in patients during the long period of illness and treatment. Particularly in recent years, with the advent of a more exhaustive analysis of genetic information and gene products, the molecular mechanisms at play during breast cancer have gradually become clearer. In the present study, a systematic review of the literature between 2009 and 2014 was conducted by searching for the keywords 'breast cancer', 'biomarkers', 'diagnosis', 'prognosis' and 'drug response' to clarify the present state of knowledge regarding biomarkers. In the final analysis, 16 studies on biomarkers for the breast cancer prognosis were retrieved. From these, 7 biomarkers in 9 studies were found to be strongly reliable predictors of prognosis and a further 7 biomarkers in 7 studies were poorly reliable. The use of these prognostic biomarkers should increase the options available for treatment algorithms.
- Published
- 2017
- Full Text
- View/download PDF
37. Flap revascularization in patients following immediate reconstruction using an autologous free dermal fat graft for breast cancer: a report of two cases.
- Author
-
Shima H, Kutomi G, Kyuno T, Satomi F, Uno S, Maeda H, Kameshima H, Omura T, Kimura Y, Mizuguchi T, Hirata K, and Takemasa I
- Abstract
It has been reported that use of the free dermal fat graft (FDFG) technique produces a good cosmetic outcome for breast cancer. An FDFG is harvested from the lower abdomen as a columnar-shaped specimen and implanted into the defect of the breast after a partial mastectomy as a volume replacement technique. In this report, two patients who underwent breast-conserving surgery with immediate reconstruction using an autologous FDFG are described in order to show the difference in status between one case with and one without blood flow in the graft. To assess the benefit of this technique using FDFGs, their cosmetic satisfaction was evaluated using a questionnaire, graft shrinkage was measured by CT, and blood flow was assessed using contrast-enhanced ultrasound (CEUS). Both patients scored 10 of 12 points on the questionnaire. After 2 years, shrinkage of the grafts was 21.6 and 25.2 %, respectively. Although one patient had no blood flow in the center of the graft, the other had blood flow from the pectoralis major muscle to the center of the graft. While satisfaction and graft shrinkage were similar in the two patients, one case showed blood flow and had a somewhat softer graft than the other. The graft status was maintained with a good cosmetic outcome for 3 years after breast-conserving surgery with immediate reconstruction using an autologous FDFG, despite mild shrinkage and hardness of the graft. It is notable that blood flow was observed into the graft on CEUS, and more distinct perfusion was seen in the softer graft case after more than 3 years.
- Published
- 2016
- Full Text
- View/download PDF
38. Hypoxia augments MHC class I antigen presentation via facilitation of ERO1-α-mediated oxidative folding in murine tumor cells.
- Author
-
Kajiwara T, Tanaka T, Kukita K, Kutomi G, Saito K, Okuya K, Takaya A, Kochin V, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Hirata K, Sato N, and Tamura Y
- Subjects
- Animals, Antigen Presentation, Disease Models, Animal, Female, H-2 Antigens metabolism, Humans, Hypoxia therapy, Melanoma therapy, Melanoma, Experimental, Mice, Mice, Inbred C57BL, Mice, Transgenic, Oxidation-Reduction, Oxidoreductases, Protein Folding, T-Lymphocytes, Cytotoxic transplantation, Tumor Microenvironment, Glycoproteins metabolism, Hypoxia immunology, Immunotherapy methods, Melanoma immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
To establish an effective cancer immunotherapy, it is crucial that cancer cells present a cancer-specific antigen in a hypoxic area, a hallmark of the tumor microenvironment. Here, we show the impact of hypoxia on MHC class I antigen presentation in vitro and in vivo in murine tumors. Activation of antigen-specific CTLs by tumor cells that had been pre-incubated under a condition of hypoxia was enhanced compared with that by tumor cells pre-incubated under a condition of normoxia. Cell surface expression of MHC class I-peptide complex on the tumor cells was increased under a condition of hypoxia, thereby leading to higher susceptibility to specific CTLs. We show that the hypoxia-inducible ER-resident oxidase ERO1-α plays an important role in the hypoxia-induced augmentation of MHC class I-peptide complex expression. ERO1-α facilitated oxidative folding of MHC class I heavy chains, thereby resulting in the augmentation of cell surface expression of MHC class I-peptide complex under hypoxic conditions. These results suggest that since the expression of MHC class I-peptide complex is augmented in a hypoxic tumor microenvironment, strategies for inhibiting the function of regulatory T cells and myeloid-derived suppressor cells and/or immunotherapy with immune checkpoint inhibitors are promising for improving cancer immunotherapy., (© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2016
- Full Text
- View/download PDF
39. Clinicopathological characteristics of thyroid cancer misdiagnosed by fine needle aspiration.
- Author
-
Maeda H, Kutomi G, Satomi F, Shima H, Mori M, Hirata K, and Takemasa I
- Abstract
Fine-needle aspiration (FNA) is commonly used as a preoperative assessment to diagnose thyroid cancer. However, misdiagnosis of malignancy by FNA is not rare, even if image examination suggests the possibility of thyroid cancer. In the present study, the clinicopathological factors of patients whose preoperative FNA examination had not led to a diagnosis of thyroid cancer were examined. In total, 125 patients with thyroid cancer who underwent FNA and surgery (total thyroidectomy, subtotal thyroidectomy or hemithyroidectomy) at the Department of Surgery, Surgical Oncology and Science of the Sapporo Medical University Hospital between 2006 and 2013 were retrospectively analyzed. The patients were divided into two groups: Group A, malignancy determined by FNA, and group B, no malignancy. The groups were then compared by gender, age, tumor size, stage, tumor stage, lymph node metastasis, histology, surgical procedure methods, presence or absence of calcification and thyroglobulin levels. The mean age of the patients in group A (5 males and 59 females) was 53.0 years. The mean age in group B (11 males and 49 females) was 54.2 years. The mean tumor size in both groups was 1.6 cm. The mean thyroglobulin levels were 82.7 ng/ml in Group A and 525.5 ng/ml in group B. There were also significant differences between the groups for tumor stage (P=0.046), histological type (P=0.024) and thyroglobulin levels (P=0.035). The results of the present study suggested that it may be difficult to diagnose thyroid cancer by FNA in cases with non-papillary carcinoma and higher thyroglobulin levels.
- Published
- 2016
- Full Text
- View/download PDF
40. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.
- Author
-
Morita R, Hirohashi Y, Torigoe T, Ito-Inoda S, Takahashi A, Mariya T, Asanuma H, Tamura Y, Tsukahara T, Kanaseki T, Kubo T, Kutomi G, Mizuguchi T, Terui T, Ishitani K, Hashino S, Kondo T, Minagawa N, Takahashi N, Taketomi A, Todo S, Asaka M, and Sato N
- Subjects
- Adenocarcinoma immunology, Adenocarcinoma pathology, Animals, Biomarkers, Tumor biosynthesis, Biomarkers, Tumor genetics, Colonic Neoplasms immunology, Colonic Neoplasms pathology, HT29 Cells, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Prognosis, RNA Interference, RNA, Small Interfering genetics, Receptors, Odorant biosynthesis, Receptors, Odorant genetics, Spheroids, Cellular, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Adenocarcinoma therapy, Biomarkers, Tumor immunology, Colonic Neoplasms therapy, Immunotherapy methods, Neoplastic Stem Cells immunology, Receptors, Odorant immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Purpose: Cancer-initiating cells (CICs) are thought to be essential for tumor maintenance, recurrence, and distant metastasis, and they are therefore reasonable targets for cancer therapy. Cancer immunotherapy is a novel approach to target cancer. In this study, we aimed to establish novel CIC-targeting immunotherapy., Experimental Design: Colorectal cancer (CRC) CICs were isolated as side population (SP) cells. The gene expression profile of CRC CICs was analyzed by cDNA microarray and RT-PCR. Protein expression of olfactory receptor family 7 subfamily C member 1 (OR7C1) were analyzed by Western blot and immunohistochemical staining. The functions of OR7C1 were analyzed by gene overexpression and gene knockdown using siRNAs. OR7C1-positive cells were isolated by a flow cytometer and analyzed. CTLs specific for OR7C1 peptide were generated, and the antitumor effect was addressed by mice adoptive transfer model., Results: OR7C1 has essential roles in the maintenance of colon CICs, and the OR7C1-positive population showed higher tumorigenicity than that of the OR7C1-negative population, indicating that OR7C1 is a novel functional marker for colon CIC. Immunohistochemical staining revealed that OR7C1 high expression was correlated with poorer prognosis in CRC patients. OR7C1-derived antigenic peptide-specific CTLs showed specific cytotoxicity for CICs, and an OR7C1-specific CTL clone showed a greater antitumor effect than did a CTL clone targeting all cancer cells in a CTL adoptive transfer mouse model., Conclusions: OR7C1 is a novel marker for colon CICs and can be a target of potent CIC-targeting immunotherapy. Clin Cancer Res; 22(13); 3298-309. ©2016 AACR., (©2016 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
41. RNA helicase YTHDC2 promotes cancer metastasis via the enhancement of the efficiency by which HIF-1α mRNA is translated.
- Author
-
Tanabe A, Tanikawa K, Tsunetomi M, Takai K, Ikeda H, Konno J, Torigoe T, Maeda H, Kutomi G, Okita K, Mori M, and Sahara H
- Subjects
- 5' Untranslated Regions, Adenocarcinoma genetics, Adenocarcinoma secondary, Adenosine Triphosphatases genetics, Animals, COS Cells, Chlorocebus aethiops, Colonic Neoplasms genetics, Colonic Neoplasms pathology, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Genes, Reporter, HCT116 Cells, HT29 Cells, Heterografts, Humans, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Mice, Inbred BALB C, Mice, Nude, Neoplasm Metastasis, Neoplasm Staging, Neoplasm Transplantation, Nuclear Proteins metabolism, RNA Helicases, RNA Interference, RNA, Messenger genetics, Signal Transduction, Time Factors, Transfection, Tumor Hypoxia, Twist-Related Protein 1 metabolism, Up-Regulation, Adenocarcinoma enzymology, Adenosine Triphosphatases metabolism, Cell Movement, Colonic Neoplasms enzymology, Hypoxia-Inducible Factor 1, alpha Subunit biosynthesis, RNA, Messenger metabolism
- Abstract
YTH domain containing 2 (YTHDC2) is a member of the DExD/H-box family of ATP-dependent RNA helicases. We previously found that YTHDC2 expression is up-regulated in several human cancer cells. In this study, we demonstrate novel roles for YTHDC2 in metastasis of colon tumor cells via translation-dependent pathway. Knockdown of YTHDC2 attenuated protein expression of metastasis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1α), and inhibited metastasis of colon tumor cells in vitro and in vivo. To confirm that YTHDC2 promotes translation initiation by unwinding the 5'-untranslated region (5'UTR) of mRNA, we constructed a firefly luciferase reporter containing the 5'UTR of the HIF-1α mRNA and showed reduction in luciferase activity in YTHDC2-silenced cells. Furthermore, we examined expression levels of YTHDC2 by immunohistochemical staining in human colon cancer tissues from 72 patients and found a significantly positive correlation between YTHDC2 expression and the tumor stage, including metastasis. In conclusion, these results suggest that the RNA helicase YTHDC2 contributes to colon tumor metastasis by promoting translation of HIF-1α and that YTHDC2 is potentially a diagnostic marker and target gene for treating colon cancer patients., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
42. SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
- Author
-
Shima H, Kutomi G, Satomi F, Maeda H, Hirohashi Y, Hasegawa T, Mori M, Torigoe T, and Takemasa I
- Subjects
- Adult, Aged, Aged, 80 and over, Aldehyde Dehydrogenase 1 Family, Breast Neoplasms mortality, Breast Neoplasms pathology, Disease-Free Survival, Female, Humans, Immunohistochemistry, Lymphatic Metastasis, Middle Aged, Prognosis, Receptors, Estrogen analysis, Retrospective Studies, Breast Neoplasms chemistry, Isoenzymes analysis, Retinal Dehydrogenase analysis, SOXB1 Transcription Factors analysis
- Abstract
Aim: Sex-determining region Y-box binding protein-2 (SOX2) and aldehyde dehydrogenase-1 (ALDH1) are known cancer stem-cell markers, and represent candidate predictors for breast cancer prognosis. In this study we investigated the relationships between SOX2/ALDH1 expression and prognosis., Materials and Methods: One hunred and two breast cancer surgical specimens were immunohistochemically analyzed for SOX2 and ALDH1 expression., Results: Disease-free survival (DFS) and overall survival (OS) were significantly poorer for SOX2-positive patients than SOX2-negative (p=0.0024 and p=0.0021, respectively), and for ALDH1-positive patients than ALDH1-negative (p=0.0049 and p=0.0083). DFS and OS were worse for SOX2- or ALDH1-positive patients than double-negative (p=0.0053 and p=0.0166). While an obvious tendency toward worse DFS was seen for estrogen receptor (ER)-negative patients, and attenuated for ER-positive, only SOX2/ALDH1 any-positive patients showed significantly poorer DFS (p=0.0258)., Conclusion: SOX2 and ALDH1 can be considered markers of poor prognosis, particularly in ER-negative patients. SOX2/ALDH1 any-positivity might also offer a reliable predictor of poor prognosis., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2016
43. Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level.
- Author
-
Tanaka T, Kutomi G, Kajiwara T, Kukita K, Kochin V, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Okamoto Y, Hirata K, Sato N, and Tamura Y
- Subjects
- Animals, Breast Neoplasms blood supply, Breast Neoplasms pathology, Cell Line, Tumor, Disulfides metabolism, Female, Gene Knockdown Techniques, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Membrane Glycoproteins genetics, Mice, Mice, Inbred NOD, Mice, SCID, Neoplasm Proteins genetics, Neoplasm Transplantation, Oxidation-Reduction, Oxidoreductases genetics, RNA, Messenger biosynthesis, RNA, Messenger genetics, RNA, Neoplasm biosynthesis, RNA, Neoplasm genetics, Reactive Oxygen Species metabolism, Triple Negative Breast Neoplasms blood supply, Triple Negative Breast Neoplasms genetics, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Gene Expression Regulation, Neoplastic, Membrane Glycoproteins physiology, Neoplasm Proteins physiology, Neovascularization, Pathologic enzymology, Oxidoreductases physiology, Protein Folding, Triple Negative Breast Neoplasms enzymology, Vascular Endothelial Growth Factor A biosynthesis
- Abstract
Background: Endoplasmic reticulum disulfide oxidase 1-α (ERO1-α) is an oxidase that exists in the endoplasmic reticulum and has a role in the formation of disulfide bonds of secreted proteins and cell-surface proteins. Recently, we reported that ERO1-α is present in high levels in various types of tumours, and that ERO1-α is a novel factor of poor prognosis. However, how ERO1-α affects a tumour in vivo and why patients who have a tumour with a high expression level of ERO1-α have a poor prognosis are still unknown. Therefore, to clarify the mechanism, we investigated the effect of ERO1-α on a tumour from the point of view of angiogenesis., Methods: The effect of ERO1-α on tumour growth and angiogenesis was analysed by using non-obese diabetic-severe combined immunodeficient mice. The production of vascular endothelial growth factor (VEGF) in MDA-MB-231 cells with ERO1-α- overexpression or with ERO1-α knockdown was measured. The role of ERO1-α on VEGF expression was investigated. In triple-negative breast cancer cases, the relationship between expression of ERO1-α and angiogenesis was analysed., Results: We found that the expression of ERO1-α promoted tumour growth in a mouse study and angiogenesis. The effects of ERO1-α on angiogenesis were mediated via oxidative protein folding of VEGF and enhancement of VEGF mRNA expression by using MDA-MB-231. In triple-negative breast cancer cases, the expression of ERO1-α related to the number of the blood vessel. Furthermore, we found that ERO1-α was a poor prognosis factor in triple-negative breast cancer., Conclusions: Our study has established a novel link between expression of ERO1-α and secretion of VEGF, providing new evidence for the effectiveness of ERO1-α-targeted therapy in patients with ERO1-α-expressed cancer.
- Published
- 2016
- Full Text
- View/download PDF
44. The Japanese Breast Cancer Society clinical practice guideline for surgical treatment of breast cancer, 2015 edition.
- Author
-
Jinno H, Inokuchi M, Ito T, Kitamura K, Kutomi G, Sakai T, Kijima Y, Wada N, Ito Y, and Mukai H
- Subjects
- Antibiotic Prophylaxis, Brain Neoplasms pathology, Brain Neoplasms secondary, Brain Neoplasms surgery, Breast Neoplasms pathology, Endoscopy methods, Female, Humans, Lymph Node Excision methods, Mammaplasty methods, Mastectomy, Segmental methods, Sentinel Lymph Node Biopsy methods, Breast Neoplasms surgery, Mastectomy methods
- Published
- 2016
- Full Text
- View/download PDF
45. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?
- Author
-
Mizuguchi T, Torigoe T, Satomi F, Shima H, Kutomi G, Ota S, Ishii M, Hayashi H, Asakura S, Hirohashi Y, Meguro M, Kimura Y, Nishidate T, Okita K, Ishino M, Miyamoto A, Hatakenaka M, Sato N, and Hirata K
- Subjects
- Bacterial Vaccines, Carcinoembryonic Antigen, Clinical Trials as Topic, Fowlpox virus, Gastrins, Genes, ras genetics, Heat-Shock Proteins, Inhibitor of Apoptosis Proteins, Kinesins, Listeria monocytogenes, Mucin-1, Mutation, Peptides, Survivin, Telomerase, Vaccines, Attenuated, Vascular Endothelial Growth Factor Receptor-2, Viral Vaccines, WT1 Proteins, Cancer Vaccines therapeutic use, Carcinoma, Pancreatic Ductal therapy, Pancreatic Neoplasms therapy
- Abstract
Pancreatic tumors are chemoresistant and malignant, and there are very few therapeutic options for pancreatic cancer, as the disease is normally diagnosed at an advanced stage. Although attempts have been made to develop vaccine therapies for pancreatic cancer for a couple of decades, none of the resultant protocols or regimens have succeeded in improving the clinical outcomes of patients. We herein review vaccines tested within the past few years, including peptide, biological and multiple vaccines, and describe the three sets of criteria used to evaluate the therapeutic activity of vaccines in solid tumors.
- Published
- 2016
- Full Text
- View/download PDF
46. Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool.
- Author
-
Matsuda Y, Okita K, Furuhata T, Kutomi G, Yamashita K, Sato Y, Takimoto R, and Hirata K
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Cross-Over Studies, Female, Hospitals, Humans, Incidence, Japan, Male, Middle Aged, Nausea chemically induced, Nausea drug therapy, Outpatients, Prospective Studies, Reproducibility of Results, Vomiting chemically induced, Vomiting drug therapy, Antiemetics therapeutic use, Nausea diagnosis, Neoplasms drug therapy, Surveys and Questionnaires, Vomiting diagnosis
- Abstract
Purpose: The Multinational Association of Supportive Care in Cancer (MASCC) developed the MASCC antiemesis tool (MAT) as a tool for chemotherapy-induced nausea and vomiting (CINV) assessment and subsequently published its Japanese version in 2010. We evaluated the validity of CINV assessment in outpatients using the Japanese version of MAT., Methods: Patients administered highly or moderately emetogenic chemotherapy in the outpatient chemotherapy unit of our hospital were included in the study. The study was designed as a prospective two-period crossover observational study to evaluate the correlation between the daily patient diary and the Japanese version of MAT in terms of CINV onset. We examined with a focus on reliability of the Japanese version of MAT particularly in the description of the delayed phase of nausea and vomiting., Results: Patient descriptions of CINV onset in a total of 116 cycles in 58 patients (two cycles/patient) were analyzed. The CINV incidence indicated by the patient diary was similar to that by the Japanese version of MAT. The concordance rate between the two tools in the same patients was 86.2 % for CINV onset in the delayed phase. The nausea score was also similar between the two tools regarding the mean and variance, showing a strong correlation with a correlation coefficient of 0.71., Conclusions: The results of the study showed that the Japanese version of MAT is a highly reliable tool for CINV assessment, indicating that it is valid for assessing CINV in outpatients.
- Published
- 2015
- Full Text
- View/download PDF
47. CpG-A stimulates Hsp72 secretion from plasmacytoid dendritic cells, facilitating cross-presentation.
- Author
-
Tanaka T, Kajiwara T, Kutomi G, Kurotaki T, Saito K, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T, Hirata K, Okamoto Y, Sato N, and Tamura Y
- Subjects
- Animals, Antigens immunology, Antigens metabolism, Cell Line, Dendritic Cells drug effects, HSP90 Heat-Shock Proteins metabolism, Humans, Ligands, Mice, Mice, Knockout, Multiprotein Complexes, Oligodeoxyribonucleotides pharmacology, Peptides immunology, Peptides metabolism, Protein Binding, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic metabolism, Toll-Like Receptor 9 genetics, Toll-Like Receptor 9 metabolism, Tumor Necrosis Factor-alpha biosynthesis, Antigen Presentation immunology, Cross-Priming immunology, Dendritic Cells immunology, Dendritic Cells metabolism, HSP72 Heat-Shock Proteins metabolism, Oligodeoxyribonucleotides immunology
- Abstract
Plasmacytoid dendritic cells (pDCs) are the main producers of IFN-α in response to unmethylated DNA molecules, including cytosine guanine dinucleotide (CpG)-DNA in vivo. pDCs specifically express toll-like receptor (TLR) 9 and are therefore able to recognize the unmethylated DNAs. It has recently been shown that not only conventional DCs (cDCs) but also pDCs efficiently cross-present exogenous antigens after TLR9 activation. However, the precise molecular mechanism has remained unclear. Here, we show that pDCs secreted heat shock protein 72 (Hsp72) in response to CpG-A administration in a TLR9-dependent manner. Extracellular Hsp72 bound to an Hsp90-peptide complex and enhanced binding of Hsp90-peptide complex to pDC, resulting in efficient cross-presentation. Our experiments therefore suggest a mechanism for orchestration of immune responses by stimulation of pDCs with CpG-A., (Copyright © 2015 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
48. Relationship of serum isoflavone, insulin and adiponectin levels with breast cancer risk.
- Author
-
Minatoya M, Kutomi G, Asakura S, Otokozawa S, Sugiyama Y, Ohnishi H, Akasaka H, Miura T, Mori M, and Hirata K
- Subjects
- Adiponectin chemistry, Adult, Asian People, Body Mass Index, Breast Neoplasms etiology, Case-Control Studies, Female, Genistein blood, Humans, Middle Aged, Molecular Weight, Postmenopause, Premenopause, Risk Factors, Adiponectin blood, Breast Neoplasms blood, Insulin blood, Isoflavones blood
- Abstract
Background: Obesity is one of the well-known risk factors of breast cancer. Accumulating evidence suggests that adiponectin, an obesity-related hormone, is inversely associated with breast cancer risk, particularly in postmenopausal women. Obesity is also associated with high levels of insulin. In addition, studies have suggested that the soy isoflavones present in the traditional Japanese diet have been associated with decreased risk of breast cancer. However, there is no study that has assessed associations between serum levels of isoflavones, insulin, adiponectin and the risk of breast cancer all together with menopausal status., Methods: In a case-control study of 63 histologically confirmed breast cancer patients and 76 controls, serum isoflavone, insulin, and high-molecular-weight (HMW) adiponectin levels and breast cancer risk were examined for their association with breast cancer risk after adjustment for various risk factors., Results: Women in the highest tertile of serum HMW adiponectin levels were associated with a statistically significant decreased risk for breast cancer compared with women in the lowest tertile [odds ratio (OR), 0.09; 95 % confidence interval (CI) 0.03-0.33]. This association was observed in postmenopausal women (OR 0.06; 95 % CI 0.01-0.28), but not in premenopausal women. The observed associations were independent of possible effects of insulin, body mass index, and known risk factors for breast cancer. Serum isoflavones and insulin levels were not associated with breast cancer risk., Conclusions: This study suggests that high serum HMW adiponectin levels are significantly associated with a decreased risk for breast cancer. Our result support the hypothesis that serum adiponectin may act as a potential biomarker for breast cancer.
- Published
- 2015
- Full Text
- View/download PDF
49. Heat shock protein 90 associates with Toll-like receptors 7/9 and mediates self-nucleic acid recognition in SLE.
- Author
-
Saito K, Kukita K, Kutomi G, Okuya K, Asanuma H, Tabeya T, Naishiro Y, Yamamoto M, Takahashi H, Torigoe T, Nakai A, Shinomura Y, Hirata K, Sato N, and Tamura Y
- Subjects
- Animals, Antibodies, Antinuclear blood, Antibodies, Antinuclear immunology, Blotting, Western, Dendritic Cells immunology, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Knockdown Techniques, Humans, Immunoprecipitation, Interferon-alpha immunology, Mice, Mice, Inbred C57BL, Mice, Inbred ICR, Mice, Inbred MRL lpr, Microscopy, Confocal, Autoantigens immunology, HSP90 Heat-Shock Proteins immunology, Lupus Erythematosus, Systemic immunology, Nucleic Acids immunology, Toll-Like Receptor 7 immunology, Toll-Like Receptor 9 immunology
- Abstract
Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease, and disease activity is associated with serum IFN-α level. Plasmacytoid dendritic cells (pDCs) sense microbial as well as self-nucleic acids by TLRs 7 and 9 and produce a large amount of IFN-α. Here, we show that heat shock protein 90 (Hsp90) associates with and delivers TLR7/9 from the ER to early endosomes for ligand recognition. Inhibition of Hsp90 by various approaches including the use of Hsp90 inhibitor, a geldanamycin derivative, suppressed the Hsp90 association with TLR7/9, which resulted in inhibition of IFN-α production, leading to improvement of SLE symptoms in mice. Notably, we observed that serum Hsp90 is clearly increased in patients with active SLE compared with that in patients with inactive disease. Furthermore, we demonstrated that serum Hsp90 detected in SLE patients binds to self-DNA and/or anti-DNA Ab, thus leading to stimulation of pDCs to produce IFN-α. Our data demonstrate that Hsp90 plays a crucial role in the pathogenesis of SLE and that an Hsp90 inhibitor will therefore provide a new therapeutic approach to SLE and other nucleic acid-related autoimmune diseases., (© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2015
- Full Text
- View/download PDF
50. A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer.
- Author
-
Kutomi G, Ohmura T, Satomi F, Maeda H, Shima H, Kameshima H, Okazaki M, Masuoka H, Sasaki K, and Hirata K
- Subjects
- Aged, Albumin-Bound Paclitaxel administration & dosage, Breast Neoplasms pathology, Breast Neoplasms secondary, Cyclophosphamide administration & dosage, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Maximum Tolerated Dose, Middle Aged, Nanoparticles, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Background: The objective of the present clinical study is to determine the maximum tolerated dose (MTD)/recommended dose (RD) of combination therapy with nanoparticle albumin-bound paclitaxel (nab-PTX) and cyclophosphamide (CPA) in patients with metastatic or recurrent breast cancer., Methods: nab-PTX and CPA were administered on the first day of each 21-day treatment cycle. The dose of CPA was fixed at 600 mg/m(2), while the dose of nab-PTX was increased from 180 mg/m(2) (Level 1) to 220 mg/m(2) (Level 2) and then to 260 mg/m(2) (Level 3)., Results: A total of 11 patients from two institutions were enrolled in the present study. At Level 3, a dose-limiting toxicity (DLT) was observed in 1 patient. Considering treatment continuity and the risk of adverse events in Cycle 2 and thereafter at this level, further subject enrollment at Level 3 was discontinued after two patients had been enrolled. Since the doses used at Level 3 were considered the MTD of nab-PTX and CPA and the doses used at Level 2 were considered the RD of nab-PTX and CPA, three additional subjects were enrolled at Level 2. No DLTs were observed at Level 2., Conclusion: The RD of combination therapy with nab-PTX and CPA was 220 mg/m(2) and 600 mg/m(2), respectively, in patients with metastatic or recurrent breast cancer.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.